In spite of an FDA panel's recommendation against Allos Therapeutics Inc.'s RSR13, the agency issued an approvable letter for the radiation sensitizer. (BioWorld Today)
Breathing a sigh of satisfaction after years of hard work, officials at Indevus Pharmaceuticals Inc. reached a long-awaited milestone on Friday with the FDA approval of Sanctura. (BioWorld Today)
As it nears a new drug application filing for its second product, Avanir Pharmaceuticals Inc. priced a $25 million common stock offering that will allow it to continue development of its pipeline products. (BioWorld Today)
